CN1275623A - Oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte and preparation and use thereof - Google Patents
Oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte and preparation and use thereof Download PDFInfo
- Publication number
- CN1275623A CN1275623A CN 99116531 CN99116531A CN1275623A CN 1275623 A CN1275623 A CN 1275623A CN 99116531 CN99116531 CN 99116531 CN 99116531 A CN99116531 A CN 99116531A CN 1275623 A CN1275623 A CN 1275623A
- Authority
- CN
- China
- Prior art keywords
- oligo
- propyl ester
- amorphophallus rivieri
- glucomannan
- sulfovindte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The present invention relates to a konjak glucomannan sulfonated derivative, i. e. oligo-konjak glucomannan aldehydic propyl ester sodium sulfovinate compound, and its preparation for making medicine and effective component for preventing and curing angiocardiopathy and cerebrovascular disease. Said invention uses konjak flour as raw material, adopts the processes of enzymolysis and debranching to obtain linear konjak glucommannan, adding acid and oxidant to make acidolysis and oxidation, and further adding epoxypropane to prepare oligo-konjak glucommannan aldehydic propyl ester in the presence of sodium hydroxide or potassium hydroxide or sodium ethylate catalyst, further using formamide-chlorosulfonic acid sulfonating aent to make sulfonation, precipitating, desalting, reprecipitating and drying in the air so as to obtain said invented compound.
Description
The present invention relates to a kind of quasi-heparin substance and preparation thereof and application, be specially oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte and preparation and application.
Rhizoma amorphophalli glucomannan is a kind of natural macromolecule amylose, has the skeleton structure close with heparin.Because its inherent biocompatibility, biodegradable, commonly used because of it is nontoxic as medical macromolecular materials, slow releasing carrier of medication or make other pharmaceutical raw materials.
China's konjaku resource is very abundant, the annual several hundred million tons of konjaku powder of producing.Rhizoma amorphophalli glucomannan in the konjaku powder (Konjac Glucomannan, be called for short KGM) accounts for more than 80%, and also starch-containing, Mierocrystalline cellulose, protein, the reducing sugar etc. that dissociates are the polysaccharide resources of demanding urgently developing.KGM is a kind of linear polysaccharide, but branched structure is often arranged.The structure difference just has different characteristics.Document " chemical structure of Rhizoma amorphophalli glucomannan and rheological property " (Xu Shiying etc., Wuxi light industry college journal, 1991, (1) report 1-11), KGM mainly contains D-seminose and D-glucose, and its mol ratio is 2: 1, with β 1.4 chain combinations, a small amount of branch is with β 1.3 chain combinations, C in the KGM molecule
2, C
3, C
6On the position-OH; all has stronger reactive behavior; under proper condition; can carry out number of chemical modifies; as acylations, sulphating, carboxymethylation and hydroxyethylation etc.; wherein the most attracting is the development of the sulfonated derivative of KGM; because sulfonated derivative is the basis of preparation heparinoid drug; the heparitin pharmacological action extensively, anticoagulation, antithrombotic, accent blood fat, reducing blood viscosity, inhibition red corpuscle or platelet aggregation, microcirculation improvement and effect hypotensive, blood sugar is arranged, can be used for the treatment and the control of hypercoagulability high blood viscosity syndromes and infraction disease.
Therefore the objective of the invention is to the konjaku powder is that raw material is produced a kind of Rhizoma amorphophalli glucomannan sulfonated derivative---oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte, it is oligo-Amorphophallus rivieri glucomannan glycan diesteras heparitin novel substance, and can the application of product aspect the control cardiovascular and cerebrovascular diseases medicament be proposed simultaneously for the method for producing.
For realizing purpose of the present invention, the preparation method of oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte is:
1, with the konjaku powder raw material, in acetic acid-sodium-acetate (PH5.5-6.0) damping fluid, constant temperature stirs enzymolysis for 40 ℃ with debranching factor ( Ec 3,2,1,4) (enzyme live in 500u), filters to such an extent that take off branch line konjak konjac glucomanna.
2, enzymolysis being taken off a Rhizoma amorphophalli glucomannan and be prepared into oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester, is 1: 5 (volume ratio) batching by linear Rhizoma amorphophalli glucomannan and 5% aqueous hydrochloric acid ratio, and constant temperature is in 70 ℃ of stirring reactions, Dropwise 5 %H
2O
2The solution acid hydrolysis oxidative is more than 3 hours, add propylene oxide, its amount is KGM/ propylene oxide mass ratio 1: 3, and add the NaOH of oligomeric konjac glucomanna quality 1% or KOH or sodium ethylate and make catalyzer, be cooled to 50 ℃, continue to stir more than 3 hours, filter, with medical ethanol washing back in 60 ℃ dry oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester.
3, (be by oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester than sulfonated reagent by 4: 1 (volume ratio) with methane amide and chlorsulfonic acid, the white thick liquid that 5 ℃ of following agitation and dropping chlorsulfonic acids of constant temperature get) is 1: 10 (volume ratio) batching, constant temperature is in 68 ℃ of stirring reactions more than 4 hours, the cooling back adds 95% ethanol sedimentation of 3 times of volumes, dialysis tubing with molecular weight cut-off 3000-8000d places deionized water wash-out salt again, transfer PH to 8 with NaOH solution, precipitate the air-dry oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte product that gets again with medical ethanol.
Its reaction formula is:
In the formula: R=-C
3H
5R '=-HSO
3N=glucose: seminose mol ratio 1: 2
M: debranching factor Ec (3,2,1,4) enzymolysis degree of branching K: acidolysis constant
The oligo-Amorphophallus rivieri glucomannan glycan diesteras that obtains has following physico-chemical property:
S content: 9.42% (elemental microanalysis method is undertaken by Experiment of Inorganic Chemstry)
Infrared absorpting light spectra (KBr pressed disc method): 3450
-1Cm, 2930cm
-1, 1640cm
-1, 1250cm
-1, 1070cm
-1, 800cm
-1
Fig. 1 is the infrared spectrogram of sulfonation hydroxypropyl KGM, heparin, hydroxypropyl KGM.
Fig. 2 is the spectrogram of low molecule KGM.
At 3440cm
-1There is strong absorption at the place, shows-the O-H stretching vibration of OH group, at 2940cm
-1Absorb by force in having, show CH
2Or-CH
3The c h bond stretching vibration of group; At wave number 1640cm
-1There is strong absorption at the place, shows-SO
3The C=S key stretching vibration of H group is at 1070cm
-1Strong absorption is arranged, show the stretching vibration of C-O-C (sugar ring); At 1250cm
-1There is strong absorption at the place, and proving also has-OSO
3The S=O key stretching vibration of-group is in 800cm
-1There is strong absorption at the place, proves the stretching vibration of C-O-S key.
Oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte (being oligo-Amorphophallus rivieri glucomannan glycan diesteras) has identical anticoagulant efficiency and stronger anti thrombotic action with heparin, oligo-Amorphophallus rivieri glucomannan glycan diesteras anticoagulating active is low, anti-bolt, thrombolysis effect are better, have the effect of atherosclerosis, adjustment blood fat simultaneously, the new drug that can be used as the control cardiovascular and cerebrovascular diseases is used.
Oligo-Amorphophallus rivieri glucomannan glycan diesteras pharmacological evaluation: the thrombolytic effect Bioexperiment is carried out the anti-atherogenic Bioexperiment with reference to " Chinese Medicine industry " magazine 1992,22 (10) 454-456: carry out with reference to " Chinese pharmacology communication " 1990 (7) 22.Experimental result shows, oligo-Amorphophallus rivieri glucomannan glycan diesteras inside and outside all has the thrombus dissolving effect, thrombus dissolving effect (the effect of 20 μ/kg) that obviously is better than the embolism-resisting enzyme that converts by human dosage No. 3 in the body of oligo-Amorphophallus rivieri glucomannan glycan diesteras 2.5mg/kg, external thrombolysis experiment shows that 6.25mg/ml oligo-Amorphophallus rivieri glucomannan glycan diesteras promptly has tangible thrombolytic effect, the heparitin that has etc. anticoagulant efficiency with oligo-Amorphophallus rivieri glucomannan glycan diesteras 25mg/ml does not then have effect, it is low to illustrate that oligo-Amorphophallus rivieri glucomannan glycan diesteras not only has an anticoagulating active, the strong characteristics of anti-bolt effect, and have thrombolytic effect preferably.In order to inquire into the mechanism of its anti-bolt, thrombolytic effect, observed oligo-Amorphophallus rivieri glucomannan and got of the influence of sugared diesteras fibrinolytic function.The result shows that oligo-Amorphophallus rivieri glucomannan glycan diesteras can obviously shorten ELT, oligo-Amorphophallus rivieri glucomannan glycan diesteras activation fiber protein dissolution system is described, improved the fibrinolysis function, the result that FDP raises and blood plasma Eg content descends is consistent with ELT result, has further confirmed the fibrinolysis activity of oligo-Amorphophallus rivieri glucomannan glycan diesteras.
Embodiment 1: konjaku powder KGM enzymolysis takes off a linear KGM experiment
In 500L acidolysis still by konjaku in Rhizoma amorphophalli glucomannan be that 1: 5 (volume ratio) feeds intake than 0.2M acetic acid-sodium-acetate (PH5.5-6.0) buffered soln, add preparation debranching factor Ec (3 respectively, 2,1,4) enzyme activity 500u, 1000u, 1500u, 40 ℃ of constant temperature, stirred in 15 minutes at interval (500r/min)/minute, each was handled 3 hours, detect its viscosity (cp), the amount of reducing sugar (mg/kg), test-results is: enzyme 1500u viscosity degradation alive is that 1000cp is following needs 1.2 hours, but residual sugar is elevated to 20mg/ml, when enzyme is lived 1000u, viscosity degradation is that 1000cp is following needs 1.8 hours, residual sugar rises to 17.5mg/ml, need 3 hours when having only enzyme to live 500u viscosity degradation 1000cp, the minimum 12.3mg/ml of residual sugar, so select low enzyme 500u alive for use, prolong the reaction times, can reach the dual purpose that reduces Rhizoma amorphophalli glucomannan viscosity and enzymolysis Rhizoma amorphophalli glucomannan.
Embodiment 2: enzymolysis takes off a line style Rhizoma amorphophalli glucomannan acidolysis, oxidation test
Acidolysis, oxygenant are a lot, tradition acidolysis agent is hydrochloric acid, sulfuric acid, oxygenant is sodium periodate, hydrogen peroxide etc., is that acid hydrolysis oxidative agent test-results is a HCl concentration of aqueous solution 5% when above with hydrochloric acid and hydrogen peroxide, Rhizoma amorphophalli glucomannan turbidity OD value (KGM (A
1cm 550nm) the OD value) below 1.283, acid number stabilizes to more than 90.
The adding mode of the amount of Rhizoma amorphophalli glucomannan acidolysis and the transformation efficiency that is oxidized to lower molecular weight konjak portuguese gansu polyose uronic acid and Rhizoma amorphophalli glucomannan amount, hydrochloric acid content, hydrogen peroxide and water, reaction times, temperature, oxygenant is relevant, and these factor interactions, adopt multifactor simulation scale-up, designed seven factors, two position levels and by Lg (2
7) orthogonal table experimentizes, and is that index compares analysis with oligo-Amorphophallus rivieri glucomannan polyuronide transformation efficiency, the results are shown in Table 1.
As can be seen from the results, K
1And K
2Size reacted the power of two levels of this factor to the transformation efficiency influence, extreme difference R has then judged each factor two levels population effect to the transformation efficiency influence.As seen to reaction conversion ratio influence bigger be No. 6 tests, illustrate in HCl, aqueous systems, adopt dropping H
2O
2Mode is favourable to improving konjak portuguese gansu polyose uronic acid transformation efficiency, and 70 ℃ of reactions of temperature are more favourable to the raising transformation efficiency than 40 ℃ of reactions 10 hours in the time of 5 hours.
The Rhizoma amorphophalli glucomannan acidolysis is used the molecular weight of gel-filtration mensuration oligo-Amorphophallus rivieri glucomannan glycan at 3000-7000D.
Using sulfated-card azoles color reaction: sample aqueous solution is made into 100 μ g/ml concentration, and with standard substance glucuronic acid preparation standard curve, qualitative, quantitative is surveyed its content that is oxidized to aldehydic acid, and calculating transformation efficiency is 67.08%.
Embodiment 3: the test of oligomeric konjac glucomanna aldehydic acid propyl ester
From the intuitive analysis of Rhizoma amorphophalli glucomannan acid hydrolysis oxidative experimental factor, can find out that its Rhizoma amorphophalli glucomannan consumption, hydrochloric acid consumption, temperature of reaction change and to think not have influence, in order to find out the propyl ester optimal conditions synchronously, when the propyl ester test, Rhizoma amorphophalli glucomannan consumption, hydrochloric acid consumption, temperature of reaction are fixed as a level, with esterification efficient (RE) % is that index compares analysis, find out esterification time, esterifying catalyst consumption, propylene oxide amount ratio and constant esterification temperature four because of dividing three levels, press L
g(3
4) quadrature experimentizes, and the results are shown in Table 2 and Fig. 3, esterification efficient is to be the result that esterification capacity that standard meter is calculated converts by the 20g propylene oxide among Fig. 3.
As seen from Table 2, optimum process condition is A
2, B
2, C
2, D, the calculating by the K value has also proved this point, the calculating of R has reflected that selected four factors are all more remarkable to the influence of esterification, but good condition of reaction times is at three level (B
3), other three factors top conditions are all second level, so for the reaction times, can not get rid of also still has better condition outside three levels, so carried out reaction times and the experiment of esterification yield relation, the results are shown in Table 3.
By table 3 as seen, esterification efficient reaches 93.06% after reaction reaches 3 hours, surpasses 3 hours efficient and improves not remarkable again.
Four level of factor as ise apparent from FIG. 3, the optimum combination (A of propylene oxide and oligo-Amorphophallus rivieri glucomannan polyuronide esterification reaction
2B
3C
2D
2), oligo-Amorphophallus rivieri glucomannan polyuronide net yield by Rhizoma amorphophalli glucomannan acidolysis, oxidation converts, the mass ratio that is Rhizoma amorphophalli glucomannan and propylene oxide is 1: 3, as catalyst reaction 3 hours, its esterification efficient can reach more than 95% at 50 ℃ of NaOH that add propylene oxide quality 1%.
Embodiment 4: the sulfonated efficiency test of oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester
With aforesaid methane amide-chlorsulfonic acid is sulphonating agent, sulfonation oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester, and under condition of different temperatures, sulphonating agent and oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester consumption adopt L by 3 levels
9(3
3) orthogonal table does experiment.Its experiment level of factor and L
9(3
3) Orthogonal experiment results such as table 4.Its sulphur content is measured in above 9 groups of experiments respectively, changeed being counted as sulfonation efficient more in molar ratio, the structure that contrasts each level is estimated.With sulfonation efficient is index The results of analysis of variance such as table 5.
Can be found out by experimental result: the usage quantity of (1) oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester and sulfonated reagent has the highly significant influence to sulfonation efficient, and variation of temperature does not have unusual effect to sulfonation efficient, and this illustrates the wider range of its sulfonation efficient.
(2) impact analysis of contrast sulfonated reagent consumption range of choice, the optimum amount of sulfonated reagent are 80%.
(3) from oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester dosage analysis, along with the minimizing of oligo-Amorphophallus rivieri glucomannan polyuronide consumption, the consumption of sulphonating agent also can reduce.
Table 1 L
8(2
7) KGM acidolysis, oxidation results
| Test number | Factor position level and listed number | |||||||
| ??KGM ??(kg) | ??HCl ??(ml) | ??H 2O 2??(ml) | Water (ml) | Time (hour) | Temperature (℃) | Acid hydrolysis oxidative roller material mode | Transformation efficiency (%) | |
| ????A | ????B | ????C | ????D | ????E | ????F | ????G | ||
| ????1 | ????1(1.006) | ????1(1500) | ????1(1500) | ????2(110) | ????2(10) | ???1(40) | 2 (drip H 2O 2) | ??37.05 |
| ????2 | ????2(2.080) | ????1 | ????2(4500) | ????2 | ????1(5) | ???1 | 1 (dripping HCl) | ??37.03 |
| ????3 | ????1 | ????2(4500) | ????2 | ????2 | ????2 | ????2(70) | ????1 | ??64.56 |
| ????4 | ????2 | ????2 | ????1 | ????2 | ????1 | ????2 | ????2 | ??56.73 |
| ????5 | ????1 | ????1 | ????2 | ????1(70) | ????1 | ????2 | ????2 | ??68.46 |
| ????6 | ????2 | ????1 | ????1 | ????1 | ????2 | ????2 | ????1 | ??87.02 |
| ????7 | ????1 | ????2 | ????1 | ????1 | ????1 | ????1 | ????1 | ??64.67 |
| ????8 | ????2 | ????2 | ????2 | ????1 | ????2 | ????1 | ????2 | ??38.19 |
| ????K 1 | ????234.68 | ????230.07 | ????245.41 | ????258.28 | ????227.34 | ????177.39 | ????253.73 | |
| ????K 2 | ????219.48 | ????224.09 | ????208.75 | ????195.88 | ????226.82 | ????276.77 | ????200.43 | |
| ?R＝K 1-K 2 | ????15.2 | ????5.98 | ????36.66 | ????62.40 | ????0.52 | ????99.38 | ????53.30 | |
Annotate: value is amount of reagent, temperature value, feed way in the bracket.
Table 2 L
9(3
4) KGM aldehydic acid propyl ester test-results
| Test number | Factor | Esterification efficient % | |||
| ????A | ????B | ????C | ????D | ||
| Propylene oxide (100g/100ml) | Reaction times (hour) | Catalyst n aOH measures (100ml) | Temperature of reaction (℃) | ||
| ????1 | ??1(18.44) | ???1(1) | ????3(1.2) | ?2(70) | ??25.62 |
| ????2 | ??2(42.06) | ???1 | ????1(0.3) | ?1(50) | ??47.36 |
| ????3 | ??3(75.09) | ???1 | ????2(0.6) | ?3(90) | ??60.58 |
| ????4 | ??1 | ???2(2) | ????2 | ?1 | ??69.32 |
| ????5 | ??2 | ???2 | ????3 | ?3 | ??76.49 |
| ????6 | ??3 | ???2 | ????1 | ?2 | ??68.42 |
| ????7 | ??1 | ???3(3) | ????1 | ?3 | ??95.86 |
| ????8 | ??2 | ???3 | ????2 | ?2 | ??53.15 |
| ????9 | ??3 | ???3 | ????3 | ?1 | |
| ????K 1 | ??206.21 | ??183.56 | ????192.22 | ?162.68 | |
| ????K 2 | ??212.54 | ??207.93 | ????218.61 | ?247.92 | |
| ????K 3 | ??190.17 | ??217.43 | ????198.09 | ?198.32 | |
| ?R＝K max-K min | ??22.37 | ??33.87 | ????26.39 | ?85.04 | |
Annotate: value is amount of reagent or temperature value in the bracket.
Table 3 reaction times and esterification efficient experimental result
| Reaction times (hour) | ????0 | ????1 | ????2 | ????3 | ????4 | ????5 |
| Esterification efficient % | ????0 | ??86.94 | ??92.72 | ??93.04 | ??93.58 | ??94.18 |
Table 4 L
9(3
3) oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester methane amide chlorsulfonic acid sulfonation Orthogonal experiment results
| Test number | Factor | Sulfonation efficient % | |||
| ????A | ????B | ????C | |||
| Oligomeric KGM aldehydic acid propyl ester % | Sulfonated reagent % | Temperature ℃ | Error | ||
| ????1 | ????1(8) | ????1(65) | ????1(30) | ????1 | ??62.9 |
| ????2 | ????1 | ????2(80) | ????2(70) | ????2 | ??85.5 |
| ????3 | ????1 | ????3(95) | ????3(120) | ????3 | ??86.4 |
| ????4 | ????2(12) | ????1 | ????2 | ????3 | ??84.6 |
| ????5 | ????2 | ????2 | ????3 | ????1 | ??91.0 |
| ????6 | ????2 | ????3 | ????1 | ????2 | ??99.7 |
| ????7 | ????3(16) | ????1 | ????3 | ????2 | ??77.1 |
| ????8 | ????3 | ????2 | ????1 | ????3 | ??88.5 |
| ????9 | ????3 | ????3 | ????2 | ????1 | ??99.2 |
| ????M 1 | ????234.8 | ????227.6 | ????253.1 | ????258.1 | |
| ????M 2 | ????282.3 | ????276 | ????269.3 | ????262.3 | ??(Σy) 2/9 |
| ????M 3 | ????262.8 | ????278.3 | ????257.5 | ????259.5 | |
| Extreme difference | ????47.5 | ????64.7 | ????11.8 | ????4.2 | |
| ????Q | ????379 | ????747 | ????46 | ????3 | |
Annotate: value is reagent concentration or temperature in the bracket.
Q＝(M
1 2+M
2 2+M
3 2)/3-(Σy)
2/9??(Σy)
2/9＝67583
Table 5 is the variance analysis of index with sulfonation efficient
| The variance title | ????Q | ????F | ????V | ????F | Significance |
| Oligomeric KGM aldehydic acid propyl ester % | ????379 | ????2 | ??189.5 | ????126 | ????* |
| Sulfonated reagent % | ????747 | ????2 | ??373.5 | ????249 | ????* |
| Temperature ℃ | ????46 | ????2 | ??2.3 | ????15.3 | |
| Error | ????3 | ????2 |
Annotate: F
0.05(2.2)=19.00 F
0.01(2.2)=99.00 * is a highly significant
Claims (4)
1, oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte compound, the compound of (1) structural formula that it is characterized in that having formula:
In the formula: R=-C
3H
5R '=-HSO
3N=glucose: seminose mol ratio 1: 2
M: debranching factor (Ec 3,2,1,4) enzymolysis degree of branching K: acidolysis constant
2, a kind of preparation method of oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte compound is characterized in that step is as follows;
(1) the konjaku powder raw material adds debranching factor (Ec3,2,1,4) (enzyme live in 500u), and in acetic acid one sodium-acetate PH5.5-6.0 damping fluid, constant temperature stirs enzymolysis for 40 ℃, filters to such an extent that take off branch line konjak konjac glucomanna;
(2) be 1: 5 batching by linear Rhizoma amorphophalli glucomannan and 5% aqueous hydrochloric acid volume ratio, constant temperature is in 70 ℃ of stirring reactions, Dropwise 5 %H
2O
2The solution acid hydrolysis oxidative is more than 3 hours, add propylene oxide, its amount is KGM: propylene oxide mass ratio 1: 3, and add the NaOH of oligomeric konjac glucomanna quality 1% or KOH or sodium ethylate and make catalyzer, being cooled to 50 ℃ stirs more than 3 hours, filter, with medical ethanol washing back in 60 ℃ dry oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester;
(3) press oligo-Amorphophallus rivieri glucomannan polyuronide propyl ester and methane amide-1: 10 batching of chlorsulfonic acid sulphonating agent volume ratio, constant temperature is in 68 ℃ of stirring reactions more than 4 hours, the cooling back adds 95% ethanol sedimentation of 3 times of volumes, dialysis tubing with molecular weight cut-off 3000-8000d places deionized water wash-out salt again, transfer PH to 8 with NaOH solution, precipitate the air-dry oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte product that gets again with medical ethanol.
3, the application of the described oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte of claim 1 in the medicine of preparation prevention or treatment cardiovascular and cerebrovascular diseases.
4, the composition of a kind of prevention or treatment cardiovascular and cerebrovascular diseases comprises the oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte of the claim 1 for the treatment of significant quantity and acceptable carrier or vehicle on pharmacology.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99116531 CN1117096C (en) | 1999-06-29 | 1999-06-29 | Oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte and preparation and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99116531 CN1117096C (en) | 1999-06-29 | 1999-06-29 | Oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte and preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1275623A true CN1275623A (en) | 2000-12-06 |
| CN1117096C CN1117096C (en) | 2003-08-06 |
Family
ID=5279335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99116531 Expired - Fee Related CN1117096C (en) | 1999-06-29 | 1999-06-29 | Oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte and preparation and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1117096C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310950C (en) * | 2002-05-14 | 2007-04-18 | 国家淀粉及化学投资控股公司 | Telerance starch made of starch of de-amylopectin by iso-anylase |
| CN100375618C (en) * | 2005-08-02 | 2008-03-19 | 武汉工业学院 | High performance composite hollow konjaku capsule and its prepn process |
-
1999
- 1999-06-29 CN CN 99116531 patent/CN1117096C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310950C (en) * | 2002-05-14 | 2007-04-18 | 国家淀粉及化学投资控股公司 | Telerance starch made of starch of de-amylopectin by iso-anylase |
| CN100375618C (en) * | 2005-08-02 | 2008-03-19 | 武汉工业学院 | High performance composite hollow konjaku capsule and its prepn process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1117096C (en) | 2003-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bao et al. | Chemical modifications of the (1→ 3)-α-D-glucan from spores of Ganoderma lucidum and investigation of their physicochemical properties and immunological activity | |
| Schweiger | Polysaccharide sulfates. I. Cellulose sulfate with a high degree of substitution | |
| US4814437A (en) | Method for preparation of sulfated polysaccharides by treating the polysaccharide with a reducing agent before sulfation | |
| US9562112B2 (en) | Carboxy-functionalized alternan | |
| Huynh et al. | Anticoagulant properties of dextranmethylcarboxylate benzylamide sulfate (DMCBSu); a new generation of bioactive functionalized dextran | |
| US20230151400A1 (en) | Biosynthetic heparin | |
| US4301153A (en) | Heparin preparation | |
| NO156129B (en) | PROCEDURE FOR PREPARING MIXTURES OF SULPHATED POLYSACCARIDES WITH A GENERAL HEPARIN POLYSACCARID STRUCTURE. | |
| JP2018513217A (en) | Antithrombin-heparin compositions and methods | |
| Chaubet et al. | Synthesis and structure—anticoagulant property relationships of functionalized dextrans: CMDBS | |
| KR0141685B1 (en) | Limulus amoebocyte lysate g-factor activation | |
| CN109160960A (en) | A kind of quasi-heparin substance sulfonation dihydroxypropylchitosan and preparation method thereof | |
| RU2319707C1 (en) | Method for preparing sulfated derivatives of arabinogalactan possessing anticoagulating and hypolipidemic activity | |
| CN1117096C (en) | Oligo-Amorphophallus rivieri glucomannan glycan aldehydic acid propyl ester sodium sulfovindte and preparation and use thereof | |
| JPH08508540A (en) | Non-anticoagulant, chemically modified heparin-like substances for the treatment of hypovolemic shock and related shock syndromes | |
| Maiga-Revel et al. | New investigations on heparin-like derivatized dextrans: CMDBS, synergistic role of benzylamide and sulfate substituents in anticoagulant activity | |
| JP4071438B2 (en) | Preparation of (1 → 3) -β-D-glucan from fungi | |
| KR920003692B1 (en) | Process for the depolymerization and sulfation of polysaccharides | |
| US5416198A (en) | Selective sorbent removal system using polycation activated substrates | |
| JP2008519595A (en) | Modified alginate and production method and use thereof | |
| JPH0369374B2 (en) | ||
| WO2003046014A1 (en) | Method for sulphonation of compounds comprising free hydroxyl (oh) groups or primary or secondary amines | |
| Wardhani et al. | Simultaneous effect of temperature and time of deacetylation on physicochemical properties of glucomannan | |
| CN103540630B (en) | A kind of preparation method of low molecular weight heparin | |
| WO2000059967A1 (en) | Functionalized glycosaminoglycan polymer and medical instruments and drugs by using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |